Alternating noncross‐resistant combination chemotherapy and active nonspecific immunotherapy with BCG or MER‐BCG for advanced breast carcinoma

G. R. Blumenschein; G. N. Hortobagyi; S. P. Richman; J. U. Gutterman; C. K. Tashima; A. U. Buzdar; M. A. Burgess; R. B. Livingston; E. M. Hersh

doi:10.1002/1097-0142(19800215)45:4<742::AID-CNCR2820450422>3.0.CO;2-X

Alternating noncross‐resistant combination chemotherapy and active nonspecific immunotherapy with BCG or MER‐BCG for advanced breast carcinoma

G. R. Blumenschein, G. N. Hortobagyi, S. P. Richman, J. U. Gutterman, C. K. Tashima, A. U. Buzdar, M. A. Burgess, R. B. Livingston, E. M. Hersh

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

One hundred fifty‐six evaluable patients with metastatic breast cancer were treated with vincristine, Adriamycin and cyclophosphamide alternating at fixed intervals with 5‐FU and methotrexate. Immunotherapy with BCG or MER‐BCG was administered to all patients in two consecutive treatment programs. Overall objective response rate and complete response rate were 67% and 20%, respectively. These were not significantly different between the two immunotherapeutic groups. The median time to progression was sixteen‐and‐a‐half months from initiation of therapy. The median survival of all patients was 21 months and that of responders was 26 months. Response rates, time to progression, and survival showed no significant advantage over a recent historical control group treated with FAC‐BCG. Toxicity related to the gastrointestinal tract and bone marrow was considerably higher in this protocol than in the FAC combinations. MER at the dose, route, and schedule administered in this protocol caused excessive local and systemic toxic reactions. The alternate use of these noncross‐resistant combinations in advanced breast cancer is not superior to combination chemotherapy used in the traditional manner. Cancer 45:742‐749, 1980.

Original language	English (US)
Pages (from-to)	742-749
Number of pages	8
Journal	Cancer
Volume	45
Issue number	4
DOIs	https://doi.org/10.1002/1097-0142(19800215)45:4<742::AID-CNCR2820450422>3.0.CO;2-X
State	Published - Feb 15 1980
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/1097-0142(19800215)45:4<742::AID-CNCR2820450422>3.0.CO;2-X

Cite this

Blumenschein, G. R., Hortobagyi, G. N., Richman, S. P., Gutterman, J. U., Tashima, C. K., Buzdar, A. U., Burgess, M. A., Livingston, R. B., & Hersh, E. M. (1980). Alternating noncross‐resistant combination chemotherapy and active nonspecific immunotherapy with BCG or MER‐BCG for advanced breast carcinoma. Cancer, 45(4), 742-749. https://doi.org/10.1002/1097-0142(19800215)45:4<742::AID-CNCR2820450422>3.0.CO;2-X

Blumenschein, GR, Hortobagyi, GN, Richman, SP, Gutterman, JU, Tashima, CK, Buzdar, AU, Burgess, MA, Livingston, RB & Hersh, EM 1980, 'Alternating noncross‐resistant combination chemotherapy and active nonspecific immunotherapy with BCG or MER‐BCG for advanced breast carcinoma', Cancer, vol. 45, no. 4, pp. 742-749. https://doi.org/10.1002/1097-0142(19800215)45:4<742::AID-CNCR2820450422>3.0.CO;2-X

@article{ff06597fca2b42db8b21d12583b9e56f,

title = "Alternating noncross‐resistant combination chemotherapy and active nonspecific immunotherapy with BCG or MER‐BCG for advanced breast carcinoma",

abstract = "One hundred fifty‐six evaluable patients with metastatic breast cancer were treated with vincristine, Adriamycin and cyclophosphamide alternating at fixed intervals with 5‐FU and methotrexate. Immunotherapy with BCG or MER‐BCG was administered to all patients in two consecutive treatment programs. Overall objective response rate and complete response rate were 67% and 20%, respectively. These were not significantly different between the two immunotherapeutic groups. The median time to progression was sixteen‐and‐a‐half months from initiation of therapy. The median survival of all patients was 21 months and that of responders was 26 months. Response rates, time to progression, and survival showed no significant advantage over a recent historical control group treated with FAC‐BCG. Toxicity related to the gastrointestinal tract and bone marrow was considerably higher in this protocol than in the FAC combinations. MER at the dose, route, and schedule administered in this protocol caused excessive local and systemic toxic reactions. The alternate use of these noncross‐resistant combinations in advanced breast cancer is not superior to combination chemotherapy used in the traditional manner. Cancer 45:742‐749, 1980.",

author = "Blumenschein, {G. R.} and Hortobagyi, {G. N.} and Richman, {S. P.} and Gutterman, {J. U.} and Tashima, {C. K.} and Buzdar, {A. U.} and Burgess, {M. A.} and Livingston, {R. B.} and Hersh, {E. M.}",

year = "1980",

month = feb,

day = "15",

doi = "10.1002/1097-0142(19800215)45:4<742::AID-CNCR2820450422>3.0.CO;2-X",

language = "English (US)",

volume = "45",

pages = "742--749",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "4",

}

TY - JOUR

T1 - Alternating noncross‐resistant combination chemotherapy and active nonspecific immunotherapy with BCG or MER‐BCG for advanced breast carcinoma

AU - Blumenschein, G. R.

AU - Hortobagyi, G. N.

AU - Richman, S. P.

AU - Gutterman, J. U.

AU - Tashima, C. K.

AU - Buzdar, A. U.

AU - Burgess, M. A.

AU - Livingston, R. B.

AU - Hersh, E. M.

PY - 1980/2/15

Y1 - 1980/2/15

N2 - One hundred fifty‐six evaluable patients with metastatic breast cancer were treated with vincristine, Adriamycin and cyclophosphamide alternating at fixed intervals with 5‐FU and methotrexate. Immunotherapy with BCG or MER‐BCG was administered to all patients in two consecutive treatment programs. Overall objective response rate and complete response rate were 67% and 20%, respectively. These were not significantly different between the two immunotherapeutic groups. The median time to progression was sixteen‐and‐a‐half months from initiation of therapy. The median survival of all patients was 21 months and that of responders was 26 months. Response rates, time to progression, and survival showed no significant advantage over a recent historical control group treated with FAC‐BCG. Toxicity related to the gastrointestinal tract and bone marrow was considerably higher in this protocol than in the FAC combinations. MER at the dose, route, and schedule administered in this protocol caused excessive local and systemic toxic reactions. The alternate use of these noncross‐resistant combinations in advanced breast cancer is not superior to combination chemotherapy used in the traditional manner. Cancer 45:742‐749, 1980.

AB - One hundred fifty‐six evaluable patients with metastatic breast cancer were treated with vincristine, Adriamycin and cyclophosphamide alternating at fixed intervals with 5‐FU and methotrexate. Immunotherapy with BCG or MER‐BCG was administered to all patients in two consecutive treatment programs. Overall objective response rate and complete response rate were 67% and 20%, respectively. These were not significantly different between the two immunotherapeutic groups. The median time to progression was sixteen‐and‐a‐half months from initiation of therapy. The median survival of all patients was 21 months and that of responders was 26 months. Response rates, time to progression, and survival showed no significant advantage over a recent historical control group treated with FAC‐BCG. Toxicity related to the gastrointestinal tract and bone marrow was considerably higher in this protocol than in the FAC combinations. MER at the dose, route, and schedule administered in this protocol caused excessive local and systemic toxic reactions. The alternate use of these noncross‐resistant combinations in advanced breast cancer is not superior to combination chemotherapy used in the traditional manner. Cancer 45:742‐749, 1980.

UR - http://www.scopus.com/inward/record.url?scp=0018843958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018843958&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19800215)45:4<742::AID-CNCR2820450422>3.0.CO;2-X

DO - 10.1002/1097-0142(19800215)45:4<742::AID-CNCR2820450422>3.0.CO;2-X

M3 - Article

C2 - 6986970

AN - SCOPUS:0018843958

SN - 0008-543X

VL - 45

SP - 742

EP - 749

JO - Cancer

JF - Cancer

IS - 4

ER -

Alternating noncross‐resistant combination chemotherapy and active nonspecific immunotherapy with BCG or MER‐BCG for advanced breast carcinoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this